stockrowInnate Pharma S.A. Sponsored ADR
IPHAInnate Pharma S.A. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $10.2 million, down 53.2% from fiscal 2024.
Follow IPHA
Alert me
Innate Pharma S.A. Sponsored ADR (IPHA) Return on invested capital
Innate Pharma S.A. Sponsored ADR's return on invested capital over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −165.6% (fiscal 2020) to 76.0% (fiscal 2018); the current reading is higher than 90% of that period. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 93.83 |
| FY2021 | −93.8% | 71.79 |
| FY2020 | −165.6% | (67.74) |
| FY2019 | −97.9% | (173.90) |
| FY2018 | 76.0% | 76.02 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| INO Inovio Pharmaceuticals, Inc. compare | 0.00% |
| STRO Sutro Biopharma, Inc. compare | 0.00% |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | 0.00% |
| IPHA Innate Pharma S.A. Sponsored ADR | 0.00% |
| ANTX AN2 Therapeutics, Inc. compare | 0.00% |
| ORMP Oramed Pharmaceuticals Inc. compare | −3.40% |
| CNTN Canton Strategic Holdings, Inc. compare | −8.11% |
| ALXO ALX Oncology Holdings Inc. compare | −673.3% |
| PEPG PepGen, Inc. compare | −2,076.3% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)